Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD1386 adaptive dose-finding study in knee osteoarthritis
2008-007797-37Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AZD-1386 in knee osteoarthritis (OA) (4 arms), sponsored by AstraZeneca. Primary endpoints: Analgesic efficacy dose-response and Change in WOMAC pain subscale. Started Jan 2009; status: terminated.
02
Drugs
AZD-1386
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on 2008-007797-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007797-37.